Related Experiment Videos

Primary pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient

K Ghosh1, S Daar, D Hiwase

  • 1Department of Haematology, College of Medicine, Sultan Qaboos University, Sultanate of Oman, India.

Haematologia
|June 7, 2000
PubMed

Insights

Splenectomized patients with beta-thalassaemia major face increased risk of Gram-negative bacterial infections, particularly P. putida meningitis. Early diagnosis and treatment are crucial for survival in this vulnerable population.

Area of Science:

  • Infectious Diseases
  • Hematology
  • Microbiology

Background:

  • Beta-thalassaemia major patients often undergo splenectomy and require frequent transfusions, altering immune function.
  • Splenectomy increases susceptibility to encapsulated bacteria, necessitating prophylactic measures like pneumococcal vaccination and penicillin.
  • Gram-negative bacilli are increasingly recognized as significant pathogens in immunocompromised individuals.

Observation:

  • A 19-year-old splenectomized patient with beta-thalassaemia major developed P. putida meningitis, an unusual and severe presentation.
  • Blood cultures were negative, highlighting diagnostic challenges in P. putida infections.
  • A 7-year review showed 11 serious infections in 46 splenectomized patients, none in 106 non-splenectomized patients.

Findings:

  • Overwhelming infections in splenectomized patients were exclusively caused by Gram-negative bacilli (Klebsiella, Pseudomonas, Aeromonas, Campylobacter).
  • Pneumococcal sepsis was prevented by vaccination and penicillin prophylaxis.
  • A concerning rise in Gram-negative bacillary sepsis poses a new threat due to lack of targeted vaccines or prophylaxis.

Implications:

  • Splenectomy in beta-thalassaemia major patients necessitates vigilance for Gram-negative infections.
  • Current prophylactic strategies are effective against S. pneumoniae but insufficient for Gram-negative pathogens.
  • Development of new vaccines or prophylactic antibiotics against Gram-negative bacilli is critical for this high-risk group.

Related Concept Videos